N

Novavax
D

NVAX

8.72000
USD
0.05
(0.58%)
مغلق
حجم التداول
136,624
الربح لكل سهم
-3
العائد الربحي
-
P/E
-4
حجم السوق
1,396,813,148
أصول ذات صلة
    A
    AEMD
    0.13530
    (31.78%)
    0.56100 USD
    A
    ALT
    0.09500
    (1.16%)
    8.27500 USD
    AZN
    AZN
    0.950
    (1.47%)
    65.370 USD
    BNTX
    BNTX
    1.810
    (1.63%)
    113.050 USD
    C
    CEMI
    0.02200
    (6.47%)
    0.35000 USD
    C
    CODX
    0.00330
    (0.45%)
    0.73000 USD
    I
    INO
    -0.01000
    (-0.54%)
    1.83000 USD
    JNJ
    JNJ
    0.890
    (0.62%)
    144.450 USD
    MRK
    MRK
    -1.390
    (-1.40%)
    98.150 USD
    MRNA
    MRNA
    -0.200
    (-0.51%)
    39.360 USD
    PFE
    PFE
    0.595
    (2.31%)
    26.360 USD
    V
    VXRT
    0.00480
    (0.79%)
    0.61260 USD
    المزيد
الأخبار

العنوان: Novavax

القطاع: Healthcare
الصناعة: Biotechnology
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.